← All trials
NCT05626140
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 28, 2021
- Primary completion
- May 31, 2022
- Completion date
- Jul 31, 2022
- First posted
- Nov 23, 2022
- Last posted
- Nov 23, 2022
- Enrollment
- 120
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Government of PakistanLead sponsor
- Riphah International UniversityCollaborator
- Riphah International UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.